ATOSClinical Trials•prnewswire•August 28, 2025 at 12:30 PM

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

Sentiment:Neutral (45)

Summary

Dr. Steven Quay, Chairman and Chief Executive Officer to participate in Fireside Chat with Emily Bodnar, HCW Biotech Research Analyst SEATTLE, Aug. 28, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company...

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 28, 2025 by prnewswire